Abstract Prostaglandin E 2 (PGE 2) is a lipid mediator of inflammation and cancer
progression. It is mainly formed via metabolism of arachidonic acid by cyclooxygenases …

Inflammation is closely linked to the abnormal phospholipid metabolism chain of
cyclooxygenase-2/microsomal prostaglandin E 2 synthase-1/prostaglandin E 2 (COX …

Oligodendrocyte-lineage cells, including NG2 glia, undergo prominent changes in various
neurodegenerative disorders. Here, we identify a neuroprotective role for NG2 glia against …

High‐throughput drug screening enables the discovery of new anticancer drugs. Although
monolayer cell cultures are commonly used for screening, their limited complexity and …

Inhibition of microsomal prostaglandin E synthase-1 (mPGES-1) results in decreased
production of proinflammatory PGE 2 and can lead to shunting of PGH 2 into the …

The majority of anti‐cancer therapies target the proliferating tumor cells, while the tumor
stroma, principally unaffected, survives, and provide a niche for surviving tumor cells …

Background and Purpose Heart failure with reduced ejection fraction (HFrEF) is a major
consequence of myocardial infarction (MI). The microsomal prostaglandin E synthase‐1 …

Abstract Microsomal Prostaglandin E Synthase 1 (mPGES-1) is the key enzyme for the
generation of the pro-inflammatory lipid mediator prostaglandin E 2 (PGE 2), which …

Abstract Increased prostaglandin E2 (PGE2) levels were detected in mitochondrial disease
patient cells harboring nuclear gene mutations in structural subunits of complex I, using a …

Background To examine the effects of BI 1029539 (GS-248), a novel selective human
microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor, in experimental models of …